PFE Pfizer Inc.

Pfizer Declares Fourth-Quarter 2024 Dividend

NEW YORK--(BUSINESS WIRE)--

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the company’s common stock, payable December 2, 2024, to holders of the Common Stock of record at the close of business on November 8, 2024. The fourth-quarter 2024 cash dividend will be the 344th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at and , , and like us on Facebook at .

Category: Finance

EN
09/10/2024

Underlying

PFEPfizer Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pfizer Inc.

 PRESS RELEASE
Free
PFE PFIZER INC.

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatm...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of...

October 11, 2024 1 EN
 PRESS RELEASE
Free
PFE PFIZER INC.

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Surviv...

NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in patients with metastatic castration-resistant prostate cancer (mCRPC). Results showed a statistically significant and clinically meaningful improvement in the final OS in all-comers (cohort 1) as well as in those patients with homologous recombination repair (H...

October 10, 2024 1 EN
 PRESS RELEASE
Free
PFE PFIZER INC.

Pfizer Declares Fourth-Quarter 2024 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the company’s common stock, payable December 2, 2024, to holders of the Common Stock of record at the close of business on November 8, 2024. The fourth-quarter 2024 cash dividend will be the 344th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the...

October 9, 2024 1 EN
 PRESS RELEASE
Free
PFE PFIZER INC.

Pfizer to Showcase Scientific Advancements in Respiratory and Other In...

NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases. “Pfizer is at the forefront of vaccine and therapeutic development in respiratory and infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer. “IDWeek 2024 provides a crucial platform t...

October 8, 2024 1 EN
 PRESS RELEASE
Free
PFE PFIZER INC.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events ...

September 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch